Budesonide 3 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
Budesonide 3 mg showed no clear difference in withdrawal due to disease worsening compared with placebo (moderate certainty).
Budesonide 3 mg showed no clear difference in corticosteroid related adverse events compared with placebo (low certainty).
Budesonide 9 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (moderate certainty).
Budesonide 9 mg probably leads to higher clinical improvement (decrease in CDAI > 100 or total CDAI < 150) ‐… compared with placebo (moderate certainty).
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
Budesonide 9 mg showed no clear difference in withdrawal due to disease worsening compared with placebo (low certainty).
Budesonide 9 mg showed no clear difference in corticosteroid related adverse events compared with placebo (moderate certainty).
It is very uncertain whether LMWH changes endoscopic remission compared with placebo (very low certainty).
Type I Interferons showed no clear difference in remission compared with placebo (moderate certainty).
Type I Interferons showed no clear difference in clinical improvement compared with placebo (moderate certainty).
Type I Interferons showed no clear difference in serious adverse events compared with placebo (low certainty).
Type I Interferons may leads to higher withdrawals due to adverse events compared with placebo (low certainty).
Methotrexate showed no clear difference in maintenance of remission compared with placebo (low certainty).
Budesonide MMX® 9 mg probably leads to higher remission (combined clinical and endoscopic remission) compared with placebo (moderate certainty).
Budesonide MMX® 6 mg showed no clear difference in endoscopic improvement compared with placebo (moderate certainty).
Budesonide MMX® 6 mg showed no clear difference in histologic remission compared with placebo (low certainty).
Budesonide MMX® 6 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
It is very uncertain whether budesonide MMX® 6 mg changes adverse events compared with placebo (very low certainty).
Budesonide MMX® 6 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).